Published
December 23, 2021
The Philippine Food and Drug Administration has given an Emergency Use Authorization (EUA) for COVID-19 treatment pill Molnupiravir (under the brand name Molnarz) ...
Published
November 23, 2021
Faberco Life Sciences, Inc. turn over today, November 23, 2021, the first batch of MOLNUPIRAVIR (Molnarz™) ...
Published
November 20, 2021
Faberco Life Sciences Inc, an emerging Philippine-based pharmaceutical company is one of the firsts to bring in COVID-19...
Published
November 11, 2020
The Philippines will soon have access to Molnupiravir, an antiviral pill to treat patients who are infected with COVID-19...
Published
November 11, 2020
Molnupiravir, the first oral anti-viral drug clinically proven to reduce the risk of hospitalization or death from known SARS-CoV-2 variants by half...
Published
November 18, 2020
THE HEALTH department asked President Rodrigo R. Duterte on Tuesday night to issue an order that will fast-track the approval process for coronavirus vaccines...
Published
November 18, 2020
The Serum Institute of India has authorized Faberco Life Sciences, Inc. as the company’s representative in the Philippines in the supply of COVID-19 vaccine it is developing with US biotech Novovax...
Published
November 18, 2020
MANILA, Philippines — Indian pharmaceutical company Serum Institute of India (SII), said to be the world’s largest vaccine producer, has committed to making available the vaccine against the coronavirus in the Philippines once it is developed...
Published
November 20, 2020
INDIAN pharmaceutical company Serum Institute of India (SII), said to be the world’s largest vaccine producer, has committed to making the Covid-19 vaccine available to the Philippines once it is developed...
Published
January 10, 2020
Serum Institute of India (SII) over the weekend announced that the Philippine government—through vaccine czar Carlito Galvez Jr.—has inked a term sheet to secure some 30 million doses of the coronavirus disease 2019 (COVID-19) vaccine Covovax set to arrive in the country by the third quarter of 2021...
Faberco Life Sciences, Inc, in partnership with Serum Institute of India (SII) is making CovovaxTM, the COVID-19 vaccine developed by Novavax available in the Philippines...
Published
March 09, 2021
National Task Force Against COVID-19 chief implementer Carlito Galvez Jr. is set to fly to India today to sign vaccine supply agreements with Novavax and the Serum Institute of India (SII)...
Published
March 11, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain..